All In MedTech

Device Trial Radar · NCT03653858

Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression

Controlled Randomized Clinical Trial to Assess Efficacy of Deep Brain Stimulation (DBS) of the slMFB in Patients With Treatment Resistant Major Depression

Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Sep 3, 2018

Primary completion

Jan 7, 2026

Study completion Jan 7, 2026

Sponsor

Lead sponsor
University Hospital FreiburgAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Boston Scientific Corporation
First posted
Aug 31, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 20 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this multicenter, randomized, sham-controlled, double blind (patient and observer blinded) clinical trial is to assess the antidepressant effect of Deep Brain Stimulation (DBS) in patients with treatment resistant major depression using the Boston Scientific implantable Vercise™ GEVIA™ DBS system compared to sham.

Conditions

  • Treatment-resistant Depression

Interventions

  • Vercise GEVIA deep brain stimulation (DBS) systemDevice

    DBS to the superolateral branch of the Medial Forebrain Bundle (slMFB)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Montgomery-Asberg Depression Rating Scale (MADRS) total scoreTime frame: 16 weeks after surgery
  2. Time to Montgomery-Asberg Depression Rating Scale (MADRS) augmentation of >5 points or clinical worsening in two consecutive visits after DBS terminationTime frame: Up to 3 months
  3. Assessment of (Serious) Adverse Events related to Investigational Medical Device and / or surgical proceduresTime frame: From IMD implantation until the end of study; assessed up to 77 weeks

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Université Grenoble Alpes

    Grenoble, France

  • University Hospital Freiburg

    Freiburg im Breisgau, Baden-Wurttemberg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.